Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11816491 | 0.90 | ALDH1A1 (0.41) | MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL11816487 | 0.90 | ALDH1A1 (0.41) | MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL2534205 | 0.86 | — | — | |
| SCHEMBL25648750 | 0.86 | MAPT (0.44) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL29084231 | 0.86 | MAPT (0.44) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL472121 | 0.86 | MAPT (0.44) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL11680930 | 0.85 | MAPT (0.42) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL11747683 | 0.85 | MAPT (0.42) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL11680934 | 0.85 | MAPT (0.42) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL11311453 | 0.82 | ALDH1A1 (0.41) | MAPTALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4410773-A2 | PROCESS FOR THE SYNTHESIS OF (S) 3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID | Northwestern University (US) | 2024-08-07 | — | — | EP | claimed |
| CN-117550991-A | Process for the synthesis of (S) -3-amino-4- (difluoromethylene) cyclopent-1-ene-1-carboxylic acid | 西北大学 | 2024-02-13 | — | — | CN | claimed |
| CN-112513006-A | Process for the synthesis of (S) -3-amino-4- (difluoromethylene) cyclopent-1-ene-1-carboxylic acid | 西北大学 | 2021-03-16 | — | — | CN | claimed |
| EP-3784649-A1 | PROCESS FOR THE SYNTHESIS OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID | Northwestern University (US) | 2021-03-03 | — | — | EP | claimed |
| US-6562861-B1 | (1R,3R,4R,1'S)-(-)-(1'-acetylamino-2 '-ethyl)butyl-4-(aminoimino)methylaminocyclopentan-1-carboxylic acid was prepd. and tested in vitro as neuraminidase inhibitor (IC50 less-than 1.mu.M). Bactericides or viricides | BIOCRYST PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | claimed |
| US-20260124201-A1 | CYCLOPENTANE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2026-05-07 | — | — | US | disclosed |
| US-20260085055-A1 | NOVEL MONOMER AND CHEMICALLY RECYCLABLE POLYMER MATERIAL COMPRISING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-26 | — | — | US | disclosed |
| US-20260035335-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250313524-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-10-09 | — | — | US | disclosed |
| EP-4600242-A1 | CYCLOPENTANE COMPOUND | Kissei Pharmaceutical Co., Ltd. (JP) | 2025-08-13 | — | — | EP | disclosed |
| US-20250236632-A1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2025-07-24 | — | — | US | disclosed |
| US-12331006-B2 | Process for the synthesis of (s) 3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid | NORTHWESTERN UNIVERSITY (US) | 2025-06-17 | — | — | US | disclosed |
| EP-0330824-A1 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of cardiac arrhythmias | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-09-06 | — | — | EP | disclosed |
| EP-0330788-A1 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of cardiac arrhythmia | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-09-06 | — | — | EP | disclosed |
| EP-0329904-A1 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of anxiety | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0329905-A1 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for increasing gastric motility | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0329902-A1 | Use of quinolizinone and quinolizine derivatives in the manufacture of medicaments for the treatment of psychosis | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0329903-A1 | Use of quinolizinone and quinolizine derivatives in the manufacture of medicaments for the treatment of glaucoma | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0329932-A2 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments | MERRELL PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0266730-A1 | Esters of hexadydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one and related compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313524-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CA, PIK3CB, PIK3CD | MAPT 3881/4885ALDH1A1 3698/4885KDM4E 2557/4885 |
| US-20250236632-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | MAPT 4167/4885ALDH1A1 305/4885KDM4E 720/4885 |
| US-20260085055-A1 | NOVEL MONOMER AND CHEMICALLY RECYCLABLE POLYMER MATERIAL COMPRISING THE SAME | MACF1, BRD7, BRD1 | MAPT 3918/4885ALDH1A1 101/4885KDM4E 175/4885 |
| US-20260035335-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CD, PIK3CG, PIK3CB | MAPT 3807/4885ALDH1A1 4597/4885KDM4E 1916/4885 |
| US-12331006-B2 | Process for the synthesis of (s) 3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid | SULT1E1, QPCT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MAPT 811/4885ALDH1A1 124/4885KDM4E 452/4885 |
| US-20260124201-A1 | CYCLOPENTANE COMPOUND | HCRTR1, HCRTR2, CNR1 | MAPT 4149/4885ALDH1A1 1144/4885KDM4E 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.